Opportunity Information: Apply for W81XWH 11 SCIRP TRPA
Apply for W81XWH 11 SCIRP TRPA
- The Dept. of the Army USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Spinal Cord Injury Translational Research Partnership Award" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420 Military Medical Research and Development.
- This funding opportunity was created on Jun 1, 2011 and posted on Jun 1, 2011.
- Applicants must submit their applications by Dec 1, 2011. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $2,400,000.00 to eligible and selected applicants.
- The number of recipients for this funding is limited to 2 candidate(s).
- Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The DoD Spinal Cord Injury Translational Research Partnership Award (TRPA) is a Department of Defense funding opportunity under the Spinal Cord Injury Research Program (SCIRP) designed to speed up the translation of promising spinal cord injury (SCI) research into practical clinical applications. The central idea is to fund tightly integrated collaborations that connect what is learned in the lab with what is observed and needed in patient care, with the expectation that these partnerships will move ideas further and faster along the bench-to-bedside (and bedside-to-bench) pathway than a single-investigator project. The program emphasizes research that is relevant to the SCI-injured military and veteran population and/or aligns with the FY11 SCIRP Areas of Encouragement.
A defining feature of this mechanism is the required partnership structure. Each application must be led by a team of two or three independent investigators referred to as "partners," and the team must be both multidisciplinary and multi-institutional. At least two distinct institutions have to be involved, and the collaboration is expected to be real and balanced, not a loose arrangement where one party simply supplies samples, data, or access to patients. The announcement is explicit that every partner must provide substantial intellectual input into the project design and execution. This includes shared responsibility for shaping the research plan, interpreting results, and making decisions that affect the translational direction of the work.
The personnel requirements are also specific. At least one partner must be a clinician, and at least one partner must have experience in SCI basic research. The clinician must be credentialed as a care provider in a relevant capacity at the institution of record, and the application biosketches should document those credentials (degrees, licenses, certifications). This requirement is meant to ensure that clinical insight is built into the project from the beginning, while also guaranteeing strong foundational expertise in SCI biology or other basic science domains needed to test mechanisms and develop interventions or enabling technologies.
From a scientific standpoint, the TRPA is meant for translational research rather than purely basic discovery or purely clinical work. Applicants are expected to show evidence that ideas will move in both directions between basic and clinical science. For example, a clinical observation might generate a hypothesis that is tested in preclinical models, and the findings might then refine patient stratification, biomarker selection, or feasibility for future clinical use. The program points applicants to established "developmental pathways" to clinical goals (referenced via an NCI resource) as a conceptual aid for structuring translation-oriented projects. Importantly, applications must include preliminary data relevant to SCI and the proposed work, signaling that the award is intended to push forward ideas that have already cleared an initial proof-of-concept threshold.
The review emphasis is framed around four major attributes: translational value (clear bench/bedside reciprocity), partnership strength (unique and necessary contributions from each partner), multi-institutional execution (at least two separate institutions, with a genuine collaborative plan), and impact (a credible path to influencing concepts or methods that accelerate clinical application). The overall expectation is that the proposed research will meaningfully change how SCI problems are approached and will set up the next steps toward clinical implementation, even if that next step is not performed within this award.
In terms of what the award will and will not support, research involving human subjects and human anatomical substances is allowed, but clinical trials are not permitted under this specific mechanism. The opportunity uses a strict definition of a clinical trial as prospective enrollment of human participants to test an intervention (such as a drug, device, biologic, surgery, rehabilitation modality, or behavioral intervention) for measurable outcomes related to safety, effectiveness, or efficacy. Projects that cross that line should instead look to the SCIRP Clinical Trial Award mechanism, which is positioned for rehabilitation-focused trials. This boundary matters because it shapes the kind of human work that is appropriate here (for example, observational studies, studies using existing samples, or non-interventional human research may be acceptable, while interventional testing is not).
For projects involving human subjects or human anatomical substances, the regulatory process includes an additional DoD-specific layer beyond standard institutional oversight. In addition to the local Institutional Review Board (IRB), DoD-funded research in this area must be reviewed by the US Army Medical Research and Materiel Command Office of Research Protections, Human Research Protection Office (HRPO). Local IRB approval is not required at the time of application submission, but applicants are warned to plan for the regulatory timeline, with at least four months recommended for the HRPO review and approval process due to detailed legal and directive-based requirements.
Administratively, this opportunity (Funding Opportunity Number W81XWH 11 SCIRP TRPA) was posted June 1, 2011, with a closing date of December 1, 2011, and an archive date of December 31, 2011. It is offered by the Department of the Army through USAMRAA under CFDA 12.420 (Military Medical Research and Development). The funding instrument is listed as a cooperative agreement and grant, with an estimated total funding amount of $2.4 million and an expectation of about two awards. Cost sharing is not required, and eligibility is broadly unrestricted (open to many entity types), subject to any clarifications in the full announcement. For access issues, the posted contact is the CDMRP Help Desk at 301-682-5507.
Overall, the TRPA is best understood as a targeted translational mechanism: it aims to fund small, high-integration teams spanning institutions and disciplines, anchored by both clinical and basic SCI expertise, with enough preliminary evidence to justify a near-term push toward clinically relevant outcomes, while stopping short of conducting an actual clinical trial within the award itself.
DoD Spinal Cord Injury Translational Research Partnership Award (TRPA) FAQs
What is the TRPA (Translational Research Partnership Award)?
The DoD Spinal Cord Injury Translational Research Partnership Award (TRPA) is a funding opportunity under the Spinal Cord Injury Research Program (SCIRP) intended to accelerate translation of promising spinal cord injury (SCI) research into practical clinical applications. It is designed specifically to move work further and faster along the bench-to-bedside (and bedside-to-bench) pathway than a single-investigator project.
What is the main purpose of this award?
The main purpose is to support tightly integrated, multi-institutional, multidisciplinary collaborations that connect laboratory findings with patient-care needs and observations. The emphasis is on translational progress, not isolated basic discovery or standalone clinical work.
How is this award different from a typical single-investigator grant?
A defining feature is the required partnership structure. Applications must be led by a team of two or three independent investigators ("partners") who work across at least two distinct institutions, contribute substantial intellectual input, and share responsibility for the translational direction of the research.
How many partners are required on an application?
Each application must be led by two or three independent investigators, referred to as partners.
Does the partnership have to be multi-institutional?
Yes. At least two distinct institutions must be involved. The program expects a genuine, balanced collaboration rather than a loose arrangement.
Does the partnership have to be multidisciplinary?
Yes. The partnership must be multidisciplinary, reflecting the goal of integrating clinical and basic science perspectives to drive translation.
What does the program mean by a "real and balanced" collaboration?
The announcement emphasizes that the collaboration should not be a situation where one party simply supplies samples, data, or patient access. Every partner is expected to provide substantial intellectual input into project design and execution, share responsibility for interpreting results, and participate in decisions that guide translational direction.
Is a clinician required as part of the partner team?
Yes. At least one partner must be a clinician.
Is basic SCI research experience required on the team?
Yes. At least one partner must have experience in SCI basic research.
What credentialing requirements apply to the clinician partner?
The clinician partner must be credentialed as a care provider in a relevant capacity at the institution of record. The application biosketches should document the clinician's credentials, including degrees, licenses, and certifications.
What kind of research does the TRPA support?
The TRPA supports translational research focused on moving knowledge and methods between basic and clinical SCI science. Projects are expected to show bench/bedside reciprocity, such as clinical observations informing hypotheses tested in preclinical models, and findings feeding back into clinically relevant decisions (for example, patient stratification, biomarker selection, or feasibility for future clinical use).
Does the program expect work to move in both directions (bench-to-bedside and bedside-to-bench)?
Yes. A central review emphasis is translational value, including clear reciprocity between clinical insights and basic/preclinical work.
Are purely basic science projects appropriate for this award?
The mechanism is intended for translational research rather than purely basic discovery. Applications should demonstrate a clear pathway toward clinically relevant outcomes and interaction between clinical and basic components.
Are purely clinical projects appropriate for this award?
The mechanism is not described as supporting purely clinical work. The intent is translational research that integrates clinical and basic science elements and advances development toward practical clinical applications.
Is preliminary data required?
Yes. Applications must include preliminary data relevant to SCI and the proposed work. This indicates the award is intended to advance projects that have already achieved an initial proof-of-concept threshold.
Does the TRPA reference any framework for planning translational progress?
Yes. The program points applicants to established "developmental pathways" to clinical goals (referenced via an NCI resource) as a conceptual aid for structuring translation-oriented projects.
What populations or priorities does the program emphasize?
The program emphasizes research relevant to the SCI-injured military and veteran population and/or research aligned with the FY11 SCIRP Areas of Encouragement.
What are the main criteria emphasized in review?
The review emphasis is framed around four major attributes: (1) translational value (bench/bedside reciprocity), (2) partnership strength (unique and necessary contributions from each partner), (3) multi-institutional execution (at least two institutions with a genuine collaborative plan), and (4) impact (a credible path to influencing concepts or methods that accelerate clinical application).
Are human subjects studies allowed under this award?
Yes. Research involving human subjects is allowed.
Are studies using human anatomical substances allowed?
Yes. Research involving human anatomical substances is allowed.
Are clinical trials allowed under this mechanism?
No. Clinical trials are not permitted under this specific mechanism.
How does this opportunity define a clinical trial?
It uses a strict definition: prospective enrollment of human participants to test an intervention (such as a drug, device, biologic, surgery, rehabilitation modality, or behavioral intervention) for measurable outcomes related to safety, effectiveness, or efficacy.
If a project includes a clinical trial, what should applicants do?
Projects that meet the clinical trial definition should instead look to the SCIRP Clinical Trial Award mechanism, which is positioned for rehabilitation-focused trials.
What types of human research may fit if clinical trials are not allowed?
Based on the stated boundary, non-interventional human research may be appropriate (for example, observational studies or studies using existing samples), while prospective interventional testing is not permitted under this mechanism.
What regulatory reviews are required for projects involving human subjects or human anatomical substances?
In addition to local Institutional Review Board (IRB) review, DoD-funded research of this type must be reviewed by the US Army Medical Research and Materiel Command Office of Research Protections, Human Research Protection Office (HRPO).
Is local IRB approval required at the time of application submission?
No. Local IRB approval is not required at the time of application submission.
How long should applicants plan for the HRPO review process?
The opportunity recommends planning at least four months for the HRPO review and approval process due to detailed legal and directive-based requirements.
What is the Funding Opportunity Number for this award?
The Funding Opportunity Number is W81XWH 11 SCIRP TRPA.
When was this opportunity posted and when did it close?
It was posted on June 1, 2011, with a closing date of December 1, 2011, and an archive date of December 31, 2011.
Which DoD components administer or offer this opportunity?
It is offered by the Department of the Army through the U.S. Army Medical Research Acquisition Activity (USAMRAA).
What is the CFDA number associated with this program?
The CFDA number is 12.420 (Military Medical Research and Development).
What type of funding instrument is used?
The funding instrument is listed as a cooperative agreement and grant.
What is the estimated total funding amount and expected number of awards?
The estimated total funding amount is $2.4 million, with an expectation of about two awards.
Is cost sharing required?
No. Cost sharing is not required.
Who is eligible to apply?
Eligibility is described as broadly unrestricted (open to many entity types), subject to any clarifications in the full announcement.
Who can applicants contact for access issues or help?
The posted contact for access issues is the CDMRP Help Desk at 301-682-5507.
What outcome is the program ultimately trying to achieve?
The expectation is that funded projects will meaningfully change how SCI problems are approached and set up the next steps toward clinical implementation, even if those next steps are not completed within the award itself.
Browse more opportunities from the same category: Science and Technology and other Research and Development
Next opportunity: Low Income Taxpayer Clinic
Previous opportunity: Transit Climate Change Adaptation Assessment Pilots
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for W81XWH 11 SCIRP TRPA
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (W81XWH 11 SCIRP TRPA) also looked into and applied for these:
| Funding Opportunity |
|---|
| Cooperative Studies Of The Earths Deep Interior Apply for 11 548 Funding Number: 11 548 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Morocco Tunisia Technology Commercialization Program Apply for S OES 11 RFA 0011 Funding Number: S OES 11 RFA 0011 Agency: Ocean and International Environmental Scientific Category: Science and Technology and other Research and Development Funding Amount: $148,500 |
| Environmental Health and Safety of Nanotechnology Apply for PD 12 1179 Funding Number: PD 12 1179 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Use of Microalgae Feedstocks in the Joint Development and Validation of a Novel Algal Lipids Extraction Technology Apply for USAFA BAA 2009 CALL 0003 Funding Number: USAFA BAA 2009 CALL 0003 Agency: Air Force Academy Category: Science and Technology and other Research and Development Funding Amount: $100,000 |
| Environmental Engineering Apply for PD 12 1440 Funding Number: PD 12 1440 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Biosensing Apply for PD 12 7909 Funding Number: PD 12 7909 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: $600,000 |
| Biotechnology, Biochemical, and Biomass Engineering Apply for PD 12 1491 Funding Number: PD 12 1491 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: $600,000 |
| Fluid Dynamics Apply for PD 12 1443 Funding Number: PD 12 1443 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Environmental Sustainability Apply for PD 12 7643 Funding Number: PD 12 7643 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Energy for Sustainability Apply for PD 12 7644 Funding Number: PD 12 7644 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Biophotonics Apply for PD 12 7236 Funding Number: PD 12 7236 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: $600,000 |
| Biomedical Engineering Apply for PD 12 5345 Funding Number: PD 12 5345 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: $600,000 |
| Catalysis and Biocatalysis Apply for PD 12 1401 Funding Number: PD 12 1401 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Particulate and Multiphase Processes Apply for PD 12 1415 Funding Number: PD 12 1415 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Thermal Transport Processes Apply for PD 12 1406 Funding Number: PD 12 1406 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Chemical and Biological Separations Apply for PD 12 1417 Funding Number: PD 12 1417 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Combustion, Fire, and Plasma Systems Apply for PD 12 1407 Funding Number: PD 12 1407 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Interfacial Processes and Thermodynamics Apply for PD 12 1414 Funding Number: PD 12 1414 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Process and Reaction Engineering Apply for PD 12 1403 Funding Number: PD 12 1403 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Cooperative Ecosystem Studies Unit, Rocky Mountain CESU Apply for G11AS20042 Funding Number: G11AS20042 Agency: Geological Survey Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "W81XWH 11 SCIRP TRPA", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.